New hope for tough colorectal cancer: LYL273 trial opens

NCT ID NCT05319314

Recruiting now Disease control Sponsor: Lyell Immunopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, LYL273, in about 155 adults with metastatic colorectal cancer that has relapsed or stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. Participants must have limited liver involvement and no surgical options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215-5418, United States
University of California San Francisco Medical Center
RECRUITING

San Francisco, California, 94143, United States
University of Colorado Hospital - Anschutz Cancer Pavilion
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.